Pharma major Novartis falls 10% after three drug trial setbacks

Novartis fell 10.5% on Tuesday after the Swiss pharmaceutical company disclosed that del-desiran, its experimental treatment for muscle-wasting disorder, failed to meet endpoints in a late-stage clinical trial. The setback marks one of three trial disappointments announced by the company, though the source details only the del-desiran program by name.

The drug was being evaluated for a rare muscle-wasting condition, and the late-stage failure raises questions about Novartis's pipeline strength in specialty therapeutics. Late-stage trial failures typically mean years of investment and development capital are written off, and the company must now pivot resources to other programs or seek external acquisitions to fill the gap.

The 10.5% decline represents a significant one-day loss for a large-cap pharmaceutical stock, signaling investor concern that the pipeline may be thinner than previously assumed. The triple-trial setback compounds the pressure, as each failed program eliminates a potential future revenue stream in a sector where blockbuster drugs drive valuations.